UNSPSC 51151612: Hyoscyamine

This classification denotes an antimuscarinic agent with the molecular formula C17H23NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier PX44XO846X, chemically known as 1alphah,5alphah-tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate but more generally known as hyoscyamine, which bears U.S. National Institutes of Health Compound Identifier 3661. European Medicines Agency schedules Hyoscyamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14160MIG.

World Health Organization schedules hyoscyamine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.

UNSPSC 51151612 Hyoscyamine is a Commodity code that in recent state and local procurement appears to capture pharmaceutical products and related medical supply acquisitions, though the single recent opportunity shows a substantial mismatch with the code's nominal pharmaceutical scope. Seminole County, Florida posted an IFB in June 2026 for naloxone and drug deactivation systems—opioid-reversal and controlled-substance disposal products that fall outside the hyoscyamine pharmaceutical family. State and local health departments and counties appear to be the primary issuing bodies under this code, though the sparse recent activity limits characterization of repeat buyers or issuing-body concentration. The opportunity required E-Verify compliance, drug-free workplace certification, workers' compensation and commercial general liability coverage, and potential FEMA compliance including adherence to the Clean Air Act and Federal Water Pollution Control Act, with a three-month probationary termination clause.

Seminole County, Florida is the only recent jurisdiction activity visible in the current opportunities block. The IFB 60459723LAS sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023, and a two-year initial contract term plus one-year renewal option on a fixed-fee basis. The code shows minimal recent state and local activity; the single visible opportunity suggests that hyoscyamine or related pharmaceutical-commodity codes may be underutilized by procurement offices for these types of medical supply acquisitions, or that purchasing bodies are tagging them inconsistently.